Skip to main content
Top
Published in: Journal of General Internal Medicine 10/2015

01-10-2015 | Original Research

Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military

Authors: Christina Brzezniak, DO, Sacha Satram-Hoang, PhD, Hans-Peter Goertz, MPH, Carolina Reyes, PhD, Ashok Gunuganti, MS, Christopher Gallagher, MD, Corey A. Carter, MD

Published in: Journal of General Internal Medicine | Issue 10/2015

Login to get access

ABSTRACT

BACKGROUND

Lung cancer is the leading cause of cancer-related death in the United States (US) Military and worldwide, with non-small cell lung cancer (NSCLC) accounting for 87 % of cases.

OBJECTIVES

Using a US military cohort who receives equal and open access to healthcare, we sought to examine demographic, clinical features and outcomes with NSCLC.

DESIGN AND PARTICIPANTS

We conducted a retrospective cohort analysis of 4,751 patients, aged ≥ 18 years and diagnosed with a first primary NSCLC between 1 January 2003 and 31 December 2013 in the US Department of Defense (DoD) cancer registry.

MAIN MEASURES

Differences by patient and disease characteristics were compared using Chi-square and t-test. Kaplan Meier curves and Cox proportional hazards regression assessed overall survival.

RESULTS

The mean age at diagnosis was 66 years, 64 % were male, 72 % were Caucasian, 41 % were diagnosed at early stage, 77 % received treatment and 82 % had a history of tobacco use. Mean age at diagnosis was highest among Caucasians (67 years) and lowest among African Americans (AA; 62 years). Asian/Pacific Islanders (PI) were more likely to be female (p < 0.0001), have adenocarcinoma histology (p = 0.0003) and less likely to have a history of tobacco use (p < 0.0001) compared to other racial/ethnic groups. In multivariable survival analysis, older age, male gender, increasing stage, not receiving treatment, and tobacco history were associated with higher mortality risk. Untreated patients exhibited a 39 % higher mortality risk compared to treated patients (HR = 1.39; 95%CI = 1.23–1.57). Compared to Caucasian patients, Asian/PIs demonstrated a 20 % lower risk of death (HR = 0.80; 95%CI = 0.66–0.96). There was no difference in mortality risk between AAs and Hispanics compared to Caucasians.

CONCLUSION

The lack of significant outcome disparity between AAs and Caucasians and the earlier stage at diagnosis than usually seen in civilian populations suggest that equal access to healthcare may play a role in early detection and survival.
Literature
1.
3.
go back to reference Surveillance Epidemiology and End Results (SEER). Stat bite: lung cancer stage at diagnosis in the United States, 1995–2001. J Natl Cancer Inst. 2005;97:1805.CrossRef Surveillance Epidemiology and End Results (SEER). Stat bite: lung cancer stage at diagnosis in the United States, 1995–2001. J Natl Cancer Inst. 2005;97:1805.CrossRef
4.
go back to reference Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Lung carcinoma symptoms–an independent predictor of survival and an important mediator of African-American disparity in survival. Cancer. 2004;101:1655–63.CrossRefPubMed Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Lung carcinoma symptoms–an independent predictor of survival and an important mediator of African-American disparity in survival. Cancer. 2004;101:1655–63.CrossRefPubMed
5.
go back to reference Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004;57:597–609.CrossRefPubMed Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004;57:597–609.CrossRefPubMed
6.
go back to reference Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125:27–37.CrossRefPubMed Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125:27–37.CrossRefPubMed
7.
go back to reference Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. Lung Cancer. 2005;47:165–72.CrossRefPubMed Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. Lung Cancer. 2005;47:165–72.CrossRefPubMed
8.
go back to reference Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer. 1996;77:1947–55.CrossRefPubMed Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer. 1996;77:1947–55.CrossRefPubMed
9.
go back to reference Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994;10:21–30.CrossRefPubMed Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol. 1994;10:21–30.CrossRefPubMed
10.
go back to reference Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002;94:284–90.CrossRefPubMed Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002;94:284–90.CrossRefPubMed
11.
go back to reference Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:407–12.CrossRefPubMed Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:407–12.CrossRefPubMed
12.
go back to reference Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:711–5.CrossRefPubMed Bryant AS, Cerfolio RJ. Impact of race on outcomes of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:711–5.CrossRefPubMed
13.
go back to reference McDavid K, Tucker TC, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med. 2003;163:2135–44.CrossRefPubMed McDavid K, Tucker TC, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med. 2003;163:2135–44.CrossRefPubMed
14.
go back to reference Fergusson RJ, Thomson CS, Brewster DH, et al. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J. 2003;21:606–10.CrossRefPubMed Fergusson RJ, Thomson CS, Brewster DH, et al. Lung cancer: the importance of seeing a respiratory physician. Eur Respir J. 2003;21:606–10.CrossRefPubMed
15.
go back to reference Fesinmeyer MD, Goulart B, Blough DK, Buchwald D, Ramsey SD. Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer. 2010;116:4810–6.PubMedCentralCrossRefPubMed Fesinmeyer MD, Goulart B, Blough DK, Buchwald D, Ramsey SD. Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer. 2010;116:4810–6.PubMedCentralCrossRefPubMed
16.
go back to reference Hardy D, Xia R, Liu CC, Cormier JN, Nurgalieva Z, Du XL. Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients. Cancer. 2009;115:4807–18.CrossRefPubMed Hardy D, Xia R, Liu CC, Cormier JN, Nurgalieva Z, Du XL. Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients. Cancer. 2009;115:4807–18.CrossRefPubMed
17.
go back to reference Zheng L, Enewold L, Zahm SH, et al. Lung cancer survival among black and white patients in an equal access health system. Cancer Epidemiol Biomarkers Prev. 2012;21:1841–7.PubMedCentralCrossRefPubMed Zheng L, Enewold L, Zahm SH, et al. Lung cancer survival among black and white patients in an equal access health system. Cancer Epidemiol Biomarkers Prev. 2012;21:1841–7.PubMedCentralCrossRefPubMed
18.
go back to reference Saeed AM, Toonkel R, Glassberg MK, et al. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the survival, epidemiology, and end results database. Cancer. 2012;118:4495–501.CrossRefPubMed Saeed AM, Toonkel R, Glassberg MK, et al. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the survival, epidemiology, and end results database. Cancer. 2012;118:4495–501.CrossRefPubMed
19.
go back to reference Yang R, Cheung MC, Byrne MM, et al. Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer. 2010;116:2437–47.PubMed Yang R, Cheung MC, Byrne MM, et al. Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer. 2010;116:2437–47.PubMed
20.
go back to reference Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:788–95.CrossRefPubMed Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:788–95.CrossRefPubMed
21.
go back to reference Brunelli A, Salati M, Refai M, et al. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:385–90 e1-2.CrossRefPubMed Brunelli A, Salati M, Refai M, et al. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:385–90 e1-2.CrossRefPubMed
22.
go back to reference Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.CrossRefPubMed Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.CrossRefPubMed
24.
go back to reference Wang SJ, Fuller CD, Thomas CR Jr. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:180–90.CrossRefPubMed Wang SJ, Fuller CD, Thomas CR Jr. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:180–90.CrossRefPubMed
25.
go back to reference Gadgeel SM, Severson RK, Kau Y, Graff J, Weiss LK, Kalemkerian GP. Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest. 2001;120:55–63.CrossRefPubMed Gadgeel SM, Severson RK, Kau Y, Graff J, Weiss LK, Kalemkerian GP. Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest. 2001;120:55–63.CrossRefPubMed
26.
go back to reference Jack RH, Gulliford MC, Ferguson J, Moller H. Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services? Br J Cancer. 2003;88:1025–31.PubMedCentralCrossRefPubMed Jack RH, Gulliford MC, Ferguson J, Moller H. Geographical inequalities in lung cancer management and survival in South East England: evidence of variation in access to oncology services? Br J Cancer. 2003;88:1025–31.PubMedCentralCrossRefPubMed
27.
go back to reference Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:25–31.CrossRefPubMed Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:25–31.CrossRefPubMed
28.
go back to reference National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91.CrossRef National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91.CrossRef
29.
go back to reference Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002;13:1087–93.CrossRefPubMed Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002;13:1087–93.CrossRefPubMed
30.
go back to reference Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.CrossRefPubMed Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.CrossRefPubMed
31.
go back to reference Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.CrossRefPubMed Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.CrossRefPubMed
32.
go back to reference Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefPubMed Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefPubMed
Metadata
Title
Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military
Authors
Christina Brzezniak, DO
Sacha Satram-Hoang, PhD
Hans-Peter Goertz, MPH
Carolina Reyes, PhD
Ashok Gunuganti, MS
Christopher Gallagher, MD
Corey A. Carter, MD
Publication date
01-10-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 10/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3280-z

Other articles of this Issue 10/2015

Journal of General Internal Medicine 10/2015 Go to the issue